<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Limited has submitted its initial disclosure under SEBI's Large Corporate framework for FY 2024-25, pursuant to the relevant SEBI operational circulars. As on 31st March 2025, the company's outstanding borrowings stood at Rs. 43.14 Crores, with a highest credit rating of BBB assigned by Acuité Ratings & Research during the previous financial year. The company has confirmed that it does not qualify as a Large Corporate under the SEBI applicability criteria, as its borrowings are well below the Rs. 500 Crore threshold. This is a routine annual compliance filing required even from non-Large Corporate entities.
This is a routine regulatory disclosure with no material impact on shareholders or stock price. It simply confirms the company remains a small borrower with a moderate credit rating and is exempt from Large Corporate obligations (such as mandatory bond issuance).